Patents by Inventor Yutaka Kawakami

Yutaka Kawakami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11598988
    Abstract: An opposing substrate as a substrate for an electro-optical device includes a transparent base member and a light shielding portion disposed on a region between pixels on the base member. The light shielding portion includes a first reflective film and a second reflective film that is disposed to overlap the first reflective film and has a reflection rate lower than that of the first reflective film, and a first protective film that covers the first reflective film is provided between the first reflective film and the second reflective film.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: March 7, 2023
    Assignee: SEIKO EPSON CORPORATION
    Inventors: Yutaka Tsuchiya, Takehiro Ono, Yusuke Kinoe, Yoshitaka Hama, Yasushi Kawakami
  • Publication number: 20220373551
    Abstract: A method for separation and detection of exosomes may include: bringing a biological sample into contact with a capture molecule, the capture molecule including a specific binding substance for an antigen expressed on a cancer cell surface, to form a complex of an exosome and the capture molecule; and a bringing the complex into contact with a detector molecule, the detector molecule including a specific binding substance for an antigen expressed on a cancer cell surface and a labeling substance, to detect the complex by using the detector molecule, in which the antigen expressed on a cancer cell surface for at least one of the capture molecule and the detector molecule is cell-surface vimentin.
    Type: Application
    Filed: October 2, 2020
    Publication date: November 24, 2022
    Applicants: JSR Corporation, KEIO UNIVERSITY
    Inventors: Seiki WAKUI, Yutaka KAWAKAMI, Tomonori YAGUCHI
  • Publication number: 20220356265
    Abstract: The purpose of the present invention is to produce a chimeric antigen receptor (CAR) specific to glypican-1 (GPC-1) and to treat squamous cell carcinoma with genetically modified cells capable of expressing the CAR. The present invention provides: a chimeric antigen receptor for use in the treatment and/or prevention of squamous cell carcinoma, said chimeric antigen receptor comprising an extracellular domain capable of binding to GPC-1, a transmembrane domain and one or multiple intracellular domains, wherein at least one of the intracellular domains is an intracellular domain containing a primary cytosolic signaling sequence or an intracellular domain containing both a primary cytosolic signaling sequence and a secondary cytosolic signaling sequence; a genetically modified cell capable of expressing the chimeric antigen receptor; and a cell preparation containing the cell.
    Type: Application
    Filed: June 22, 2022
    Publication date: November 10, 2022
    Applicants: Keio University, Iwate Medical University
    Inventors: Tomonori YAGUCHI, Kenji MORII, Yutaka KAWAKAMI, Daiki KATO, Tetsuji NAKA, Satoshi SERADA, Minoru FUJIMOTO
  • Patent number: 11370845
    Abstract: The purpose of the present invention is to produce a chimeric antigen receptor (CAR) specific to glypican-1 (GPC-1) and to treat squamous cell carcinoma with genetically modified cells capable of expressing the CAR. The present invention provides: a chimeric antigen receptor for use in the treatment and/or prevention of squamous cell carcinoma, said chimeric antigen receptor comprising an extracellular domain capable of binding to GPC-1, a transmembrane domain and one or multiple intracellular domains, wherein at least one of the intracellular domains is an intracellular domain containing a primary cytosolic signaling sequence or an intracellular domain containing both a primary cytosolic signaling sequence and a secondary cytosolic signaling sequence; a genetically modified cell capable of expressing the chimeric antigen receptor; and a cell preparation containing the cell.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: June 28, 2022
    Assignees: Keio University, NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY
    Inventors: Tomonori Yaguchi, Kenji Morii, Yutaka Kawakami, Daiki Kato, Tetsuji Naka, Satoshi Serada, Minoru Fujimoto
  • Publication number: 20220133813
    Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.
    Type: Application
    Filed: February 8, 2019
    Publication date: May 5, 2022
    Applicant: Keio University
    Inventors: Kenya Honda, Takeshi Tanoue, Yutaka Kawakami, Koji Atarashi, Satoru Morita, Ashwin Nicholas Skelly
  • Patent number: 11167018
    Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: November 9, 2021
    Assignees: Keio University, The University of Tokyo
    Inventors: Kenya Honda, Takeshi Tanoue, Masahira Hattori, Yutaka Kawakami
  • Publication number: 20210023025
    Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.
    Type: Application
    Filed: October 9, 2020
    Publication date: January 28, 2021
    Applicant: THERAVALUES CORPORATION
    Inventors: Yutaka KAWAKAMI, Tomonori YAGUCHI, Taeko HAYAKAWA, Atsushi IMAIZUMI
  • Publication number: 20200383981
    Abstract: The disclosure provides a composition for inhibiting the growth and/or invasion of tumor cells, an enhancer of an anti-tumor effect of a drug for the purpose of removing immunosuppression caused by cancer, or the like, which is characterized by being used for a specific subject.
    Type: Application
    Filed: June 29, 2018
    Publication date: December 10, 2020
    Applicant: Keio University
    Inventors: Nobuo Tsukamoto, Yutaka Kawakami
  • Publication number: 20200376029
    Abstract: A medicament for cancer treatment includes as an active ingredient T cells having a chimeric antigen receptor that binds to glypican 1 (GPC1). The medicament is administered concomitantly with an immune checkpoint inhibitor according to regimens (a) and (b) to maintain the anti-tumor activity of the T cells: The regimens include (a) administering an effective amount of the T cells to a cancer patient and (b) continuously administering 0.01 mg/kg body weight to 100 mg/kg body weight of the immune checkpoint inhibitor per dose to the cancer patient every 1 to 5 weeks.
    Type: Application
    Filed: May 14, 2020
    Publication date: December 3, 2020
    Inventors: Daiki Kato, Tomonori Yaguchi, Yutaka Kawakami, Seiki Wakui, Toru Shoji, Ayuko Matsui
  • Patent number: 10849862
    Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: December 1, 2020
    Assignee: THERAVALUES CORPORATION
    Inventors: Yutaka Kawakami, Tomonori Yaguchi, Taeko Hayakawa, Atsushi Imaizumi
  • Publication number: 20200344982
    Abstract: [Problem] To provide an enclosure that can be easily cleaned, [Solution] A fish-breeding enclosure including: a frame 3 constituting the sides of a cuboid; a first net 11 covering a right side surface 5, a bottom surface 7, and a left side surface 9 of the frame 3; a first net feeder 19 for feeding the first net 11 and a second net 17 that covers a front surface 13, the bottom surface 7, and a rear surface 15 of the frame 3; and a second net feeder 21 for feeding the second net 17. When the first net 11 or the second net 17 is renewed. the first net 11 or the second net 17 is drawn out from the first net feeder 19 or the second net feeder 21, respectively.
    Type: Application
    Filed: January 10, 2019
    Publication date: November 5, 2020
    Applicant: SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
    Inventors: Ryoichi NAGATA, Yutaka KAWAKAMI
  • Publication number: 20200254079
    Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.
    Type: Application
    Filed: January 17, 2020
    Publication date: August 13, 2020
    Applicants: Keio University, The University of Tokyo
    Inventors: Kenya Honda, Takeshi Tanoue, Masahira Hattori, Yutaka Kawakami
  • Publication number: 20200221733
    Abstract: To provide a feed that does not pollute rearing water, improves the immunity activity of leptocephalus larvae, is capable of directly feeding eel leptocephalus, and is capable of effectively inducing the growth of said larvae into glass eels. This micro-encapsulated aquaculture feed includes: an oil phase 11 having an oil-soluble nutrient component; a water phase 13 which is present inside the oil phase 11, and which includes a water-soluble nutrient component; and a film 15 which includes the oil phase 11 and the water phase 13. The water-soluble nutrient component includes at least one hydrolysate from among hydrolysates of amino acids, oligopeptides, and proteins.
    Type: Application
    Filed: March 31, 2020
    Publication date: July 16, 2020
    Inventors: Ryoichi NAGATA, Yutaka KAWAKAMI
  • Patent number: 10695412
    Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: June 30, 2020
    Assignees: Keio University, The University of Tokyo
    Inventors: Kenya Honda, Takeshi Tanoue, Masahira Hattori, Yutaka Kawakami
  • Publication number: 20200093103
    Abstract: Anguilliformes breeding water contains a thyroid hormone such as thyroxine, and a method for rearing anguilliformes includes a step for administering a thyroid hormone such as thyroxine, wherein the amount of the thyroid hormone to be administered changes as the anguilliforme fingerling changes from a transformation start phase (stage 1) to a transformation final phase (stage 2), and the amount of the thyroid hormone to be administered in the transformation final phase (stage 2) is less than the amount of the thyroid hormone to be administered in the transformation start phase (stage 1).
    Type: Application
    Filed: December 27, 2017
    Publication date: March 26, 2020
    Applicant: SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
    Inventors: Ryoichi Nagata, Yutaka Kawakami
  • Publication number: 20200093871
    Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.
    Type: Application
    Filed: December 22, 2017
    Publication date: March 26, 2020
    Inventors: Kenya Honda, Takeshi Tanoue, Masahira Hattori, Yutaka Kawakami
  • Patent number: 10576136
    Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: March 3, 2020
    Assignees: Keio University, The University of Tokyo
    Inventors: Kenya Honda, Takeshi Tanoue, Masahira Hattori, Yutaka Kawakami
  • Publication number: 20190381111
    Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.
    Type: Application
    Filed: May 24, 2019
    Publication date: December 19, 2019
    Inventors: Kenya Honda, Takeshi Tanoue, Masahira Hattori, Yutaka Kawakami
  • Publication number: 20190343944
    Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.
    Type: Application
    Filed: May 24, 2019
    Publication date: November 14, 2019
    Inventors: Kenya Honda, Takeshi Tanoue, Masahira Hattori, Yutaka Kawakami
  • Publication number: 20190192458
    Abstract: Provided are a novel therapeutic or prophylactic agent for graft-versus-host disease, a novel agent for inhibiting fibrocyte infiltration, and a novel agent for inhibiting a decrease in tear secretion and a decrease of goblet cells. A method of treating or preventing graft-versus-host disease comprises administering a phenylbutyric acid or a pharmacologically acceptable salt thereof to a patient in need of treatment or prevention of graft-versus-host disease. It is preferable that the graft-versus-host disease be a graft-versus-host disease that manifests after bone marrow transplantation. It is preferable that the graft-versus-host disease be ocular graft-versus-host disease.
    Type: Application
    Filed: April 5, 2017
    Publication date: June 27, 2019
    Inventors: Shin MUKAI, Yoko OGAWA, Kazuo TSUBOTA, Yutaka KAWAKAMI